Inovio Pharmaceuticals Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Inovio Pharmaceuticals şirketinin toplam hissedar öz sermayesi $73.5M ve toplam borcu $0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $107.1M ve $33.5M dir.

Anahtar bilgiler

Borç/özkaynak oranı

US$0

Borç

Faiz karşılama oranı	n/a
Nakit	US$84.80m
Eşitlik	US$73.54m
Toplam yükümlülükler	US$33.52m
Toplam varlıklar	US$107.06m

Son finansal sağlık güncellemeleri

Güncelleme yok

Recent updates

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: INO * 'nin kısa vadeli varlıkları ( $91.3M ) kısa vadeli yükümlülüklerini ( $23.5M ) aşıyor.

Uzun Vadeli Yükümlülükler: INO * şirketinin kısa vadeli varlıkları ( $91.3M ) uzun vadeli yükümlülüklerini ( $10.0M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: INO * borçsuzdur.

Borcun Azaltılması: INO * şirketinin 5 yıl önce borç/öz sermaye oranı 194% iken borcu yok.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: INO * şirketinin mevcut serbest nakit akışına göre bir yıldan az nakit akışı süresi bulunmaktadır.

Tahmini Nakit Akışı: INO * un, serbest nakit akışı her yıl % 7.5 oranında tarihi oranda azalmaya devam ederse bir yıldan az nakit akışı süresi vardır

Inovio Pharmaceuticals Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Recent updates

Third quarter 2024 earnings released: US$0.89 loss per share (vs US$1.52 loss in 3Q 2023)

Inovio Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 14, 2024

Inovio Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $60 million.

New major risk - Financial position

New minor risk - Profitability

Second quarter 2024 earnings released: US$1.19 loss per share (vs US$1.61 loss in 2Q 2023)

Inovio Pharmaceuticals, Inc. Receives Advanced Therapy Medicinal Product Certificate from European Medicines Agency for Quality and Non-Clinical Data for Lead Candidate INO-3107

Inovio Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 08, 2024

INOVIO Announces INO-3107 Receives the Innovation Passport Designation Under U.K. Government's Innovative Licensing and Access Pathway

INOVIO Appointsof Steven Egge as Chief Commercial Officer

First quarter 2024 earnings released: US$1.31 loss per share (vs US$1.89 loss in 1Q 2023)

Inovio Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 13, 2024

Inovio Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $35.937522 million.

Inovio Pharmaceuticals, Inc., Annual General Meeting, May 21, 2024

Full year 2023 earnings released: US$6.09 loss per share (vs US$14.07 loss in FY 2022)

Inovio Pharmaceuticals, Inc. to Report Q4, 2023 Results on Mar 06, 2024

Third quarter 2023 earnings released: US$0.13 loss per share (vs US$0.15 loss in 3Q 2022)

Inovio Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Inovio Pharmaceuticals, Inc. Receives FDA Feedback That Data from Completed Phase 1/2 Trial of INO-3107

New minor risk - Market cap size

Second quarter 2023 earnings released: US$0.13 loss per share (vs US$0.46 loss in 2Q 2022)

Inovio Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 09, 2023

Inovio Pharmaceuticals, Inc.(NasdaqGS:INO) dropped from Russell 2000 Value Index

First quarter 2023 earnings released: US$0.16 loss per share (vs US$0.36 loss in 1Q 2022)

INOVIO Presents New Data from A Phase 1/2 Trial of INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis

Inovio Pharmaceuticals, Inc. to Report Q4, 2022 Results on Mar 01, 2023

Inovio Pharmaceuticals, Inc. to Report Q4, 2022 Results on Mar 01, 2023

Inovio Reports Positive Phase 1B Results for INO-4201 as an Ebola Booster for rVSV-Zebov (Ervebo®)

Inovio Pharmaceuticals, Inc. Announces Strategic Reorganization and 11% Reduction of Full-Time Employees

Third quarter 2022 earnings released: US$0.15 loss per share (vs US$0.29 loss in 3Q 2021)

INOVIO Provides Update on COVID-19 Heterologous Booster Vaccine Candidate, INO-4800

Inovio Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 08, 2022

INOVIO Reports Positive Interim Phase 1/2 Results for INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis

Second quarter 2022 earnings released: US$0.46 loss per share (vs US$0.39 loss in 2Q 2021)

Inovio Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 09, 2022

INOVIO Announces Survival Results for INO-5401 + INO-9012 in Combination with Libtayo(R) (cemiplimab) in Patients with Newly Diagnosed GBM

INOVIO Announces Board Changes

First quarter 2022 earnings released: US$0.36 loss per share (vs US$0.27 loss in 1Q 2021)

No longer forecast to breakeven

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

No longer forecast to breakeven

Inovio Pharmaceuticals, Inc. to Report Q4, 2021 Results on Mar 01, 2022

High number of new directors

INOVIO Updates on Phase 3 Program for VGX-3100 for HPV-Associated Cervical High-Grade Squamous Intraepithelial Lesions

No longer forecast to breakeven

Third quarter 2021 earnings released: US$0.29 loss per share (vs US$0.12 profit in 3Q 2020)

INOVIO Receives Regulatory Authorization to Conduct Phase 3 Efficacy Trial of its COVID-19 DNA Vaccine Candidate, INO-4800, in Mexico

Forecast to breakeven in 2023

INOVIO Receives Authorization to Conduct Phase 3 Efficacy Trial of its Covid-19 DNA Vaccine Candidate, INO-4800

Second quarter 2021 earnings released: US$0.39 loss per share (vs US$0.83 loss in 2Q 2020)

INOVIO and Advaccine Receive Regulatory Allowance for Two Heterologous Prime-Boost Clinical Trials in China Using INO-4800, INOVIO's COVID-19 DNA Vaccine Candidate

INOVIO Doses First Participant in Phase 2 Trial for its DNA Vaccine against Middle East Respiratory Syndrome, a Coronavirus Disease

Inovio Pharmaceuticals, Inc.(NasdaqGS:INO) dropped from Russell 3000 Growth Index

Forecast breakeven pushed back to 2024

Inovio's Pan-Covid-19 Vaccine Candidate (INO-4802) Induces Broad Immunity Against Major Viral Variants in Preclinical Studies

First quarter 2021 earnings released: US$0.27 loss per share (vs US$0.26 loss in 1Q 2020)

INOVIO Announces Positive Data from Phase 2 Segment of Clinical Trial Evaluating INO-4800, its COVID-19 DNA Vaccine

INOVIO Announces the Appointment of Michael Cordera As Executive Vice President & General Counsel

INOVIO Announces Positive Results from REVEAL 1, Phase 3 Pivotal Trial Evaluating VGX-3100, its DNA-Based HPV Immunotherapy for the Treatment of High-Grade Precancerous Cervical Dysplasia Caused by HPV-16 and/or HPV-18

Full year 2020 earnings released: US$1.07 loss per share (vs US$1.21 loss in FY 2019)

Revenue beats expectations

QIAGEN N.V. and Inovio Pharmaceuticals Announces an Extension of Their Partnership with A New Master Collaboration Agreement to Develop Liquid Biopsy-Based Companion Diagnostic Cervical Dysplasia

INOVIO Announces First Subject Dosed in Phase 1B Clinical Trial for its DNA Vaccine Against Lassa Fever, INO-4500, in West Africa

New 90-day high: Mex$306

Inovio Pharmaceuticals, Inc. to Report Q4, 2020 Results on Mar 01, 2021

New 90-day high: Mex$253

Inovio Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $150.45 million.

INOVIO's VGX-3100 Demonstrates Positive Phase 2 Efficacy in Treatment of Precancerous Vulvar Dysplasia Caused by HPV-16/18

INOVIO and Advaccine Announce Exclusive Partnership To Commercialize COVID-19 DNA Vaccine Candidate, INO-4800, in Greater China

INOVIO Announces Publication of Phase 1 Data from its COVID-19 DNA Vaccine Candidate, INO-4800 in The Lancet's EClinicalMedicine

Inovio Pharmaceuticals, Inc. Doses First Subject in Phase 2 Segment of its INNOVATE Phase 2/3 Clinical Trial for INO-4800, its DNA Medicine to Prevent COVID-19

INOVIO Announces Dosing of First Subject in Phase 1/2 Clinical Trial for INO-3107, its DNA Medicine to Treat a Rare Disease Recurrent Respiratory Papillomatosis (RRP)

Inovio Presents Clinical Results of Its DNA Medicines INO-5401 + INO-9012 in Novel Combination with PD-1 Inhibitor Libtayo® (Cemiplimab) in the Treatment of Newly Diagnosed Glioblastoma Multiforme At Society for Neuro-Oncology 2020 Annual Meeting

Inovio Pharmaceuticals, Inc. Announces Initiation of Phase 2 Segment of Its Phase 2/3 Clinical Trial for Its Covid-19 Dna Vaccine Candidate

Revenue misses expectations